Stockreport

Mirum: Maintaining Buy Rating On VOLIXIBAT PSC Treatment Data Q2 2026 [Seeking Alpha]

Mirum Pharmaceuticals, Inc. - common stock  (MIRM) 
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm Check Earnings Report
PDF Key catalysts include VISTAS topline data in Q2 2026, VANTAGE topline data in H1 2027, and phase 3 EXPAND enrollment completion in 2026. Company strengthened its bala [Read more]